Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety, PK, and EEG study of BCI-838 in healthy adults
NL-OMON37895Active, not recruiting
- Sponsor
- BrainCells Inc.
- Start
- Feb 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) and affective disorder comparing BCI-838 with Placebo (2 arms). Primary endpoint: Safety and tolerability of BCI-838. Started Feb 2012; status: active, not recruiting.
02
Drugs
BCI-838
03
Conditions
major depressive disorder (MDD)affective disorder
Beyond the preview
Go deeper on NL-OMON37895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37895.